A WHO report on Friday told that more than 3 people in the world have now been affected by an untreatable ‘superbug’ strain of gonorrhea, something that they are most likely to be spreading to others through coitus. This was considered a matter of extreme relevance and experts say that the highly drug-resistant strain evolves quickly and it was only a matter of time before the last resort antibiotics become obsolete.
In regard to the bug, a specialist at WHO said that Gonorrhea is a smart bug and evolves quickly to any new antibiotics that it is exposed to and develops resistance to the antibiotics. The WHO estimate of people suffering from gonorrhea is at 78 million people a year. Gonorrhea has no symptoms of its own but causes the infected person to have pelvic inflammatory disease, ectopic pregnancy, infertility and in some rare cases HIV. The disease is spread mainly through sexual contacts.
WHO has been closely monitoring the trends that have appeared in a study. It was noted that from 2009 to 2014, Gonorrhea developed resistance to the first line medicine ciprofloxacin, then to some mild antibiotics like azithromycin and in more than 50 countries resistance to last-resort antibiotics like extended-spectrum cephalosporins (ESCs). In many countries, last-resort drugs, like the ESCs, are the only line of defense against Gonorrhea. The situation is quite terrifying and there is a pressing need for new drugs to which the bug has not developed any resistance to yet. The possibility that a new drug would be released to the public is very low as there are only three new drugs that are currently under development and there is no assurance that they would pass the final-stage trials.
There is a pressing need for new drugs that are difficult to develop resistance against. They also need to be affordable and easily accessible so that anyone who has been affected can have access to the drug and help prevent the disease from spreading. The drug should also be administered properly in order to prevent any other side effects.